Milestone Pharmaceuticals (Milestone Pharmaceuticals) Median PS Value : $0.00 (As of Apr. 27, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Milestone Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Milestone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.023. Milestone Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-27), Milestone Pharmaceuticals's share price is $1.54. Milestone Pharmaceuticals's Median PS Value is $0.00. Therefore, Milestone Pharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Milestone Pharmaceuticals's Median PS Value or its related term are showing as below:

MIST's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.65
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Milestone Pharmaceuticals Median PS Value Historical Data

The historical data trend for Milestone Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Pharmaceuticals Median PS Value Chart

Milestone Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Median PS Value

Get a 7-Day Free Trial

Milestone Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Median PS Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Milestone Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Milestone Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Milestone Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Milestone Pharmaceuticals's Price-to-Median-PS-Value falls into.

Milestone Pharmaceuticals Median PS Value Calculation

Milestone Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0.023	*	0
	=	0.00

10-Year Median PS Ratio is 0.
Milestone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.023.

Milestone Pharmaceuticals (NAS:MIST) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Milestone Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	1.54	/	0.00
	=

Milestone Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Milestone Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6

Website

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.

Executives

Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha	officer: Chief Medical Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak	director	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson	officer: Chief Operating Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija	officer: CFO & EVP of Corp. Development	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller	officer: Chief Commercial Officer	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6